Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Boehringer Ingelheim
Farmers Insurance
Queensland Health
Fish and Richardson
US Department of Justice

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018780

« Back to Dashboard
NDA 018780 describes HUMULIN R KWIKPEN, which is a drug marketed by Lilly and is included in one NDA. It is available from three suppliers. Additional details are available on the HUMULIN R KWIKPEN profile page.

The generic ingredient in HUMULIN R KWIKPEN is insulin human. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin human profile page.

Summary for 018780

Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details

Pharmacology for NDA: 018780


Suppliers and Packaging for NDA: 018780

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
insulin recombinant human
INJECTABLE;INJECTION 018780 NDA Eli Lilly and Company 0002-8215 0002-8215-01 1 VIAL in 1 CARTON (0002-8215-01) > 10 mL in 1 VIAL
insulin recombinant human
INJECTABLE;INJECTION 018780 NDA Eli Lilly and Company 0002-8215 0002-8215-17 1 VIAL in 1 CARTON (0002-8215-17) > 3 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Oct 28, 1982TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength1500 UNITS/3ML (500 UNITS/ML)
Approval Date:Dec 29, 2015TE:RLD:Yes

Summary for product number 004

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength10000 UNITS/20ML (500 UNITS/ML)
Approval Date:Mar 31, 1994TE:RLD:Yes
Patent:► SubscribePatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus